A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Previously Treated RAS-Mutated Advanced or Metastatic Solid Tumors
Latest Information Update: 23 Aug 2024
At a glance
- Drugs IMM 1 104 (Primary) ; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Ductal carcinoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Immuneering
- 31 Jul 2024 According to an Immuneering Corporation media release, company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024.
- 07 May 2024 According to an Immuneering Corporation media release, results from the Phase 1 portion of this Phase 1/2a study presented at the American Association for Cancer Research (AACR) Annual Meeting.
- 14 Mar 2024 According to an Immuneering Corporation media release, company plans to present further data from the ongoing Phase 1 portion of its Phase 1/2a study of IMM-1-104 in advanced RAS-mutant solid tumors at a future medical meeting.